Cybin

CYBN

Market cap $152M

NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.

NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today highlights significant clinical and regulatory milestones and upcoming value-driving catalysts as the Company advances multiple programs towards potential commercialization. "We have established a leading position.

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).

NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.